[3H]idazoxan binding to the ovine myometrium. Binding characteristics and changes due to steroid hormones
- PMID: 1971023
[3H]idazoxan binding to the ovine myometrium. Binding characteristics and changes due to steroid hormones
Abstract
[3H]Idazoxan binding to myometrial membranes was investigated in four groups of ewes under different steroid hormone status: control, estradiol-treated and progesterone plus estradiol-treated ovariectomized ewes and pregnant ewes. [3H]Idazoxan binding to myometrial membrane fractions was saturable, reversible, specific and of high affinity. The affinity did not vary significantly between the four groups of ewes (2.8 less than KD less than 4.7 nM). Maximal binding capacity varied significantly among groups: binding of [3H]idazoxan was lower in control ovariectomized ewes than in either estradiol or progestagen plus estrogen-treated ewes (maximal binding capacity, 73 +/- 11 fmol/mg of protein vs. 108 +/- 16 and 318 +/- 65, respectively). The highest [3H]idazoxan binding was measured in pregnant ewes (maximal binding capacity, 1302 +/- 256 fmol/mg of protein). Based on the saturation studies with accurate nonspecific binding definition (phentolamine vs. epinephrine), and on the relative order of potency for selected adrenergic drugs, it could be stated that the binding sites labeled by [3H]idazoxan in our study exhibited most of the alpha-2 adrenoceptor properties. Nevertheless, these alpha-2 adrenoceptors obviously differed from the standard alpha-2A-subtype based on Ki values obtained with yohimbine and prazosin in competition studies of [3H]idazoxan binding. The increase in the number of alpha-2 adrenoceptors under progesterone domination, and especially during gestation, supported the hypothesis that this adrenoceptor subtype could play a major role in the control of the motility pattern of the ovine pregnant uterus.
Similar articles
-
Influence of steroid hormone treatments or pregnancy on [3H]prazosin and [3H]rauwolscine binding to myometrial alpha-adrenoceptors in the ewe.J Endocrinol. 1990 Dec;127(3):471-9. doi: 10.1677/joe.0.1270471. J Endocrinol. 1990. PMID: 1704044
-
Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites.Mol Pharmacol. 1990 Jun;37(6):876-85. Mol Pharmacol. 1990. PMID: 1972775
-
Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain.J Pharmacol Exp Ther. 1987 Jun;241(3):1092-8. J Pharmacol Exp Ther. 1987. PMID: 2885406
-
Non-alpha 2-adrenoceptor idazoxan binding sites; a new target for drug development.Biochem Soc Trans. 1992 Feb;20(1):113-8. doi: 10.1042/bst0200113. Biochem Soc Trans. 1992. PMID: 1353030 Review. No abstract available.
-
Autoradiography of adrenoceptors in rat and human brain: alpha-adrenoceptor and idazoxan binding sites.Prog Brain Res. 1991;88:271-91. doi: 10.1016/s0079-6123(08)63816-9. Prog Brain Res. 1991. PMID: 1667546 Review.
Cited by
-
Identification of functional alpha-adrenoceptor subtypes in the bovine female genital tract during different phases of the oestrous cycle.Vet Res Commun. 2002 Aug;26(6):479-94. doi: 10.1023/a:1020594509855. Vet Res Commun. 2002. PMID: 12241101